Vivogenia · Preclinical Operating System
The connective
tissue for
preclinical research.
A ligand binds two things that couldn't otherwise meet. Our platform does the same for preclinical research — binding vendors, proposals and project data into a single system, so scientists stay scientists.
Currently in active use across Vivogenia's client engagements — expanding to public access in Phase 1.
The problem
Researchers are great at the science. Nothing else about the pathway is built for them.
Knowledge
The scientists behind a therapy rarely have the specialised expertise to design a rigorous preclinical pathway.
"What are the exact experiments I need to satisfy regulators?"
Network
Even with a study designed, the testing landscape is thousands of niche, unlisted labs deep — with no shared directory.
"How do I find the right company to run my study?"
Complexity
Even once a program starts, scientists are forced into logistics — chasing timelines instead of running experiments.
"Is the project on track? Is the data reliable?"
The solution
One binding site for the whole pipeline.
For years, Vivogenia has been the single point of contact for clients navigating preclinical research — replacing a fragmented, opaque process with expert-led infrastructure.
That work was manual and labour-intensive. Ligand is how we're turning it into a system: crystalizing what we've learned about vendors, proposals and project delivery into a platform anyone can use.
Put simply
Ligand is a travel agent for a trip you've never planned.
Book a complex trip yourself and you become an expert overnight: comparing airlines you've never heard of, rebooking every hotel by hand when your dates shift, tracking confirmations across a dozen inboxes.
A good travel agent already knows the reliable carriers, updates every leg at once when plans change, and hands you one itinerary instead of ten. Ligand does that for a preclinical study — the researcher still owns the destination, they just stop running the logistics.
Planning it yourself
- Which airline, which hotel?
- Rebooking 5 vendors by hand
- Checking 10 inboxes for updates
With Ligand
- Vendor Search
- Proposal & Negotiation
- Project Coordination
The platform
Three points of friction. One place to dissolve them.
Vendor search
There's no universal language across preclinical labs — an "efficacy assay" at one site can mean something entirely different at another. Ligand's AI reads vendor catalogs, sites and project history to match on substance, not vocabulary.
Proposal & negotiation
Science is iterative. When a dosage group or timepoint changes, every vendor thread shouldn't need a separate email. One edit, drafted with AI, reaches every shortlisted vendor at once.
Project coordination
A proposal is not a project plan. Ligand translates the high-level PDF into granular milestones, files and status — one hour saved from logistics is one hour back in the lab.
Proportional oversight
Rigor scales to a project's actual risk profile — no administrative drag for a lean team.
Mutual value
A flexible structure that satisfies vendor compliance without slowing client agility.
Pre-vetted efficiency
Vetting happens once, centrally — removing repeat diligence from every new partnership.
Due diligence
Rigor without the drag.
Traditional due diligence frameworks are built for large pharma, not lean biotech teams. Ligand centralises vetting so every partnership starts pre-qualified — proportional, mutual, and done once.
Where we're headed
From internal tool to public ecosystem.
Phase 1
Public access
Opening the platform to academic institutions, independent researchers and emerging biotechs.
Phase 2
Advanced project management
Agentic task scheduling, proposal-to-project automation and live schedule monitoring.
Phase 3
Service integrations
Connecting Ligand to the industry-standard tools labs and sponsors already run on.
Phase 4
Community
Webinars and shared best practice, built with the researchers using the platform.
Get in touch
Have a project that needs binding together?
Whether you're weighing an initial consultation or exploring a partnership, we'd like to hear from you.